3,533 results match your criteria Polymyalgia Rheumatica


Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina.

Reumatol Clin (Engl Ed) 2022 May;18(5):286-292

Servicio de Reumatología, Hospital J. M. Ramos Mejia, Urquiza 609, Ciudad Autónoma de Buenos Aires, Argentina.

Background: Off-label (OL) drug use is the prescription of a drug for indications other than those authorised in its technical datasheet. The objective of this study was to identify drugs recommended in rheumatology but considered for off-label use in Argentina.

Methods: A list of medications for certain selected rheumatic conditions was compiled. Read More

View Article and Full-Text PDF

Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data.

Semin Arthritis Rheum 2022 Apr 28;55:152017. Epub 2022 Apr 28.

Department of Rheumatology, University Hospital Basel, Basel, Switzerland. Electronic address:

Objectives: To determine the prevalence and predictors of subclinical giant cell arteritis (GCA) in patients with newly diagnosed polymyalgia rheumatica (PMR).

Methods: PubMed, Embase, and Web of Science Core Collection were systematically searched (date of last search July 14, 2021) for any published information on any consecutively recruited cohort reporting the prevalence of GCA in steroid-naïve patients with PMR without cranial or ischemic symptoms. We combined prevalences across populations in a random-effect meta-analysis. Read More

View Article and Full-Text PDF

Pericardial effusion in giant cell arteritis is associated with increased inflammatory markers: a retrospective cohort study.

Rheumatol Int 2022 May 7. Epub 2022 May 7.

Assistance Publique des Hôpitaux de Marseille (APHM), Hôpital Nord, Service de Médecine Interne, Aix-Marseille Université (AMU), Marseille, France.

Objective: Giant cell arteritis (GCA) is the most frequent vasculitis affecting adults aged > 50 years. Cardiac involvement in GCA is considered rare, and only a few cases of pericarditis have been reported. The aim of this study was to determine the characteristics and prognosis of GCA patients suffering from pericardial involvement at diagnosis. Read More

View Article and Full-Text PDF

[Rheumatic polymyalgia is a rarely diagnosed, but often occurring disease in elderly patients.]

Adv Gerontol 2022 ;35(1):140-145

Saint-Petersburg Institute of Bioregulation and Gerontology, 3 Pr. Dynamo, St. Petersburg 197110, Russian Federation.

Verification of the diagnosis of rheumatic polymyalgia at the reception of a general practitioner, geriatrician presents significant difficulties due to the lack of pathognomonic signs of the disease. The «calling card» of the disease is a combination of severe pain in the proximal muscle groups in combination with a high acute inflammatory response. Read More

View Article and Full-Text PDF

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

Semin Arthritis Rheum 2022 Apr 15;55:152010. Epub 2022 Apr 15.

Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States.

Glucocorticoids (GCs) have been the cornerstone of treating dozens of inflammatory conditions for more than seven decades. GC toxicity is ubiquitous in both clinical trials and clinical practice, and toxicities associated with GC use are central to the experience of most patients being treated for immune-mediated conditions. These conditions span the full range of medical specialties, including rheumatology, nephrology, gastroenterology, neurology, pulmonology, ophthalmology, and others. Read More

View Article and Full-Text PDF

Treatment and Outcomes of Acute Myocardial Infarction in Patients With Polymyalgia Rheumatica With and Without Giant Cell Arteritis.

Am J Cardiol 2022 Apr 23. Epub 2022 Apr 23.

Keele Cardiovascular Research Group, Center for Prognosis Research, Keele University, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom. Electronic address:

This study analyzed the characteristics, management, and outcomes of patients with polymyalgia rheumatica (PMR) hospitalized with acute myocardial infarction (AMI), including sensitivity analysis for presence of giant cell arteritis (GCA). Using the National Inpatient Sample (January 2004 to September 2015) and International Classification of Diseases, Ninth Revision, all AMI hospitalizations were stratified into main groups: PMR and no-PMR; and subsequently, PMR, PMR with GCA, and GCA and no-PMR. Outcomes were all-cause mortality, major adverse cardiovascular/cerebrovascular events (MACCEs), major bleeding, and ischemic stroke as well as coronary angiography (CA) and percutaneous coronary intervention (PCI). Read More

View Article and Full-Text PDF

Vertebral osteomyelitis and epidural abscess due to - case report and review of literature.

J Bone Jt Infect 2022 13;7(2):75-79. Epub 2022 Apr 13.

Division of Infectious Diseases, University of Arizona, Tucson, Arizona, USA.

We describe a case of native vertebral osteomyelitis (NVO) secondary to in a patient with polymyalgia rheumatica receiving chronic steroids. Treatment required surgical debridement of the epidural phlegmon and combination therapy with intravenous ampicillin and gentamicin. Read More

View Article and Full-Text PDF

Baseline Factors Associated with Self-reported Disease Flares Following COVID-19 Vaccination among Adults with Systemic Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Rheumatology (Oxford) 2022 Apr 23. Epub 2022 Apr 23.

Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS, National Institutes of Health (NIH), Bethesda, MD, USA).

Objective: To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD).

Methods: An international study was conducted from April 2 to August 16, 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination, and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression. Read More

View Article and Full-Text PDF

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering.

Front Immunol 2022 5;13:860877. Epub 2022 Apr 5.

Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy.

Background: Inferential statistical methods failed in identifying reliable biomarkers and risk factors for relapsing giant cell arteritis (GCA) after glucocorticoids (GCs) tapering. A ML approach allows to handle complex non-linear relationships between patient attributes that are hard to model with traditional statistical methods, merging them to output a forecast or a probability for a given outcome.

Objective: The objective of the study was to assess whether ML algorithms can predict GCA relapse after GCs tapering. Read More

View Article and Full-Text PDF

Polymyalgia Rheumatica or Late Onset Lupus? A Case Report.

J Investig Med High Impact Case Rep 2022 Jan-Dec;10:23247096221089493

Medical University of South Carolina, Charleston, USA.

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a peak age of presentation between the 15 and 40 years with a wide variety of disease manifestations. Although there is no formal definition, late onset SLE is generally defined in the literature as onset after the age of 50. It is estimated that 2% to 20% of patients with SLE overall fall into this category. Read More

View Article and Full-Text PDF

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.

Trials 2022 Apr 15;23(1):318. Epub 2022 Apr 15.

Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.

Background: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC) remain the cornerstone of treatment, but these have several drawbacks. Firstly, a large proportion of patients do not achieve GC-free remission within either the first (over 70%) or second year of treatment (over 50%). Read More

View Article and Full-Text PDF

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures between Inflammatory and Non-inflammatory Aortic Aneurysms.

Arthritis Rheumatol 2022 Apr 11. Epub 2022 Apr 11.

Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

Objective: To identify hallmark genes and biomolecular processes in aortitis using high-throughput gene expression profiling. Additionally, to provide a range of potentially new drug targets (genes) and therapeutics from a pharmacogenomic network analysis.

Methods: Bulk RNA-seq was performed on surgically resected ascending aortic tissues from inflammatory (giant cell arteritis [GCA] with or without polymyalgia rheumatica [PMR] = 8; clinically isolated aortitis [CIA] = 17) and non-inflammatory (n = 25) aneurysms undergoing surgical aortic repair. Read More

View Article and Full-Text PDF

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.

Front Pharmacol 2022 25;13:803706. Epub 2022 Mar 25.

Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.

Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Read More

View Article and Full-Text PDF

Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica.

Rheum Dis Clin North Am 2022 May;48(2):493-506

Vanderbilt University Medical Center 1161 21st Avenue South, T-3113 Medical Center North Nashville, TN 37232-2681, USA. Electronic address:

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are considered 2 diseases on the same spectrum due to their many underlying similarities. In recent years, both diseases have witnessed both diagnostic and treatment advances, which shaped the way we manage them. In this article, the authors focus on different diagnostic modalities in GCA as well as the presence of different clinical phenotypes and the role of screening for aortic involvement. Read More

View Article and Full-Text PDF

Rheumatic Complications of Immune Checkpoint Inhibitors.

Rheum Dis Clin North Am 2022 May;48(2):411-428

Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA. Electronic address:

Immune checkpoint inhibitors activate the immune system to combat cancer. In doing so, however, they can cause immune-related adverse events (irAEs), including rheumatic syndromes, such as inflammatory arthritis, polymyalgia rheumatica, and myositis. This article reviews rheumatic irAEs that may be encountered in the general medicine practice and provides guidance to support prompt recognition, referral, and treatment of these patients. Read More

View Article and Full-Text PDF

Patient mit "Polymyalgia rheumatica": Diagnose kritisch überprüfen.

Authors:
Elke Oberhofer

MMW Fortschr Med 2022 04;164(7):16

Springer Medizin, München, Germany.

View Article and Full-Text PDF

Chronic meningitis misdiagnosed as polymyalgia rheumatica and successfully treated with voriconazole.

Clin Case Rep 2022 Apr 4;10(4):e05664. Epub 2022 Apr 4.

Department of Neuropathology University Medicine Göttingen Göttingen Germany.

The outcome of chronic meningitis depends to a large degree on the causative pathogen and the interval between onset of symptoms and diagnosis. We present a patient with a delayed diagnosis and several complications, for whom adequate therapy resulted in a favorable outcome. In a 76-year-old male patient,   meningitis was diagnosed 4 months after the onset of symptoms. Read More

View Article and Full-Text PDF

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.

Oncologist 2022 Apr;27(4):e353-e356

Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epithelial tumors (TETs) due to defects in immune tolerance. Read More

View Article and Full-Text PDF

A Peculiar 18F-FDG Spinal Uptake Helps Diagnosis and Effective Treatment of Polymyalgia Rheumatica: "The Corset Sign".

Clin Nucl Med 2022 Mar 30. Epub 2022 Mar 30.

Dipartimento della Continuità e dell'Integrazione, Programma Dipartimentale di Gestione delle Malattie Reumatiche e del Connettivo e Malattie Metaboliche dell'Osso, Istituto di Ricovero e Cure a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna.

Abstract: Polymyalgia rheumatica is the most common inflammatory rheumatic disease in elderly people, usually develops in patients older than 50 years, more frequently in females. An emerging imaging tool in the diagnostic workup of this condition is whole-body PET/CT, which allows an overall assessment of the articular and extra-articular structures involved. Read More

View Article and Full-Text PDF

A Case Report of Post COVID19 Giant Cell Arteritis and Polymyalgia Rheumatica With Visual Loss.

Clin Med Insights Case Rep 2022 21;15:11795476221088472. Epub 2022 Mar 21.

Department of Rheumatology, Al-Azhar University Faculty of Medicine for Girls, Cairo, Egypt.

COVID-19 shares some features of giant-cell arteritis, in which the diagnosis needs a high suspicion for prompt investigation and therapy. When the diseases coexist this might lead to diagnosis delay with grave consequences. We reported a case of a post-COVID-19 giant cell arteritis and polymyalgia rheumatica with visual loss. Read More

View Article and Full-Text PDF

Polymyalgia Rheumatica Following COVID-19 Vaccination: A Case Report.

Intern Med 2022 Mar 26. Epub 2022 Mar 26.

Department of Neurology, Fukuoka University School of Medicine, Japan.

We herein report a 71-year-old woman presented with a fever, arthralgia, general malaise and leg muscle stiffness following administration of the COVID-19 mRNA vaccine (Comirnaty, Pfizer-BioNTech). Laboratory findings showed an elevated C-reactive protein level and erythrocyte sedimentation rate. In addition, Gallium-67 scintigraphy demonstrated an increased uptake in multiple joints. Read More

View Article and Full-Text PDF

The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.

J Pers Med 2022 Feb 22;12(3). Epub 2022 Feb 22.

Library and Knowledge Services, Central and North West London NHS Foundation Trust, London NW1 3AX, UK.

Background: Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR) therapy, but their long-term use (as is usually necessary in PMR patients) can induce many adverse events. Alternatives have long been sought. The primary aim of our narrative review is to provide an overview about the use of anti-tumor necrosis factor alpha (TNF-α) drugs in patients with PMR, and discuss advantages and disadvantages. Read More

View Article and Full-Text PDF
February 2022

Getting It Right for Polymyalgia Rheumatica.

Rheumatology (Oxford) 2022 Mar 21. Epub 2022 Mar 21.

Polymyalgia Rheumatica & Giant Cell Arteritis UK, London, UK.

View Article and Full-Text PDF

Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.

Clin Rheumatol 2022 May 16;41(5):1597-1601. Epub 2022 Mar 16.

Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

The Pfizer-BioNTech COVID-19 vaccine has been authorized by the U.S. Food and Drug Administration as it demonstrated 95% effectiveness against the SARS-CoV-2 virus. Read More

View Article and Full-Text PDF

On the use of F FDG PET-CT in spondyloarthritis. Comment on : "Use of F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practice" by Pean de Ponfilly-Sotier M, et al. Joint Bone Spine. 2021;89:105325.

Joint Bone Spine 2022 Mar 11:105377. Epub 2022 Mar 11.

Department of Rheumatology, Besançon University Hospital, 25020 Besançon, France; PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, UFR Santé, 25020 Besançon, France. Electronic address:

View Article and Full-Text PDF

Usefulness of Ultrasound as a Predictor of Elderly-Onset Rheumatoid Arthritis with Polymyalgia Rheumatica-Like Onset.

Mod Rheumatol 2022 Mar 14. Epub 2022 Mar 14.

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Objectives: Differentiation between polymyalgia rheumatica (PMR) and elderly onset rheumatoid arthritis (EORA), especially in elderly patients, is often difficult due to similarities in symptoms and serological kinetics. In this study, we aimed to analyze the predictors of EORA with PMR-like onset.

Methods: Seventy-two patients diagnosed with PMR, who attended our hospital for routine care and underwent musculoskeletal ultrasonography (MSUS) at that time were evaluated. Read More

View Article and Full-Text PDF

Chronic Steroid Use Causing Spinal Epidural Lipomatosis.

Cureus 2022 Feb 5;14(2):e21945. Epub 2022 Feb 5.

Internal Medicine, Hackensack Meridian Ocean University Medical Center, Brick, USA.

Chronic steroid use causes aberrant fat deposition in the epidural space, which may in rare cases result in spinal epidural lipomatosis (SEL). We discuss the case of a 79-year-old female who had been on steroids for a long time, initially for polymyalgia rheumatica (PMR), then for adrenal insufficiency. Her dose was raised with a few steroid stress doses to control the flare of adrenal insufficiency. Read More

View Article and Full-Text PDF
February 2022

Normal ESR, CRP and Platelet Count in Giant Cell Arteritis and Polymyalgia Rheumatica: A Diagnostic Conundrum.

Eur J Case Rep Intern Med 2022 21;9(2):003192. Epub 2022 Feb 21.

Division of General Internal Medicine and Geriatrics, Oregon Health and Science University, Portland, OR, USA.

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are both rheumatological diseases of the elderly with a strong association with each other and which rarely present with normal inflammatory markers. Here we present the case of a 61-year-old Caucasian woman who had typical symptoms of both diseases. At the time of presentation, her blood work showed normal inflammatory markers, but because of the high clinical suspicion for GCA, a temporal artery biopsy was done which was positive for giant cells and disruption of the internal elastic lamina. Read More

View Article and Full-Text PDF
February 2022